It is a big relief for Patients who are taking regular therapies for disease like diabetes as it will lower the burden on their pockets by cutting cost by whooping 70%. As per the survey done by ICMR ‐ INDIAB between October 2008 and December 2020, there were 11.4 percent of diabetic patients taking regular treatment of the same in India.
The drug is being marketed under the brand name Lirafit following approval from the Drug Controller General of India (DCGI). Priced at Rs. 100 for a standard daily dose of 1.2mg, the drug will be available only under prescription.
Surprisingly this is the game changer for any diabetic patient out there in India.
It not only helps in diabetes but also helps in lowering glycemic parameters, weight reduction, and cardiovascular safety in patients with type 2 diabetes mellitus.
Though there are more chances that this will be groundbreaker for the company as well in future , shares of this Indian Pharma major started with a marginally downward trend today at Rs. 888.50 at 9:40 AM on the NSE. According to IQVIA sales data for the 12 months ended August 2023 (MAT August 2023), the market for GLP‐1 RA in India is estimated at Rs 259 crore, with an annual growth of 108 percent over last year (MAT August 2022).
